XML 37 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER
 12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER
In September 2024, the Company recorded an expense of $32.9 million related to severance expenses associated with a global workforce realignment impacting approximately 360 employees. The following table presents details of the restructuring liability, which is included in Accrued and Other Liabilities:

 Restructuring Liability
 (in millions)
Balance at December 31, 2023
$— 
Restructuring charges32.9 
Payments(12.8)
Balance at December 31, 2024
$20.1 

The Company's remaining severance obligations are expected to be substantially paid within the next 12 months.

On June 3, 2024, the Company entered into a definitive agreement to sell its Critical Care product group ("Critical Care") to Becton, Dickinson and Company ("BD") and the sale closed on September 3, 2024. In the fourth quarter of 2024, the Company recorded expenses of $19.0 million, primarily related to costs incurred for consulting, legal, tax, and other professional advisory services associated with the sale. For further information, see Note 5.
In September 2022, the Company decided to exit its HARPOON surgical mitral repair system program. As a result, the Company recorded expenses to its United States segment of $62.3 million, of which $60.7 million was included in Restructuring Charges, Separation Costs, and Other and $1.6 million was included in Cost of Sales on the consolidated statements of operations. The expenses primarily related to the full impairment of intangible assets associated with the technology for $52.7 million and other related exit costs. In September 2022, the Company recorded an $11.7 million contingent consideration gain associated with the exit and believes that no additional consideration is due. For further information, see Note 20.